Essex Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-4,235
| Closed | -$1.09M | – | 328 |
|
|
2023
Q3 | $1.09M | Sell |
4,235
-777
| -16% | -$208K | 0.18% | 184 |
|
|
2023
Q2 | $1.43M | Hold |
5,012
| – | – | 0.2% | 158 |
|
|
2023
Q1 | $1.39M | Sell |
5,012
-360
| -7% | -$99.6K | 0.2% | 154 |
|
|
2022
Q4 | $1.49M | Sell |
5,372
-1,302
| -20% | -$368K | 0.23% | 133 |
|
|
2022
Q3 | $1.78M | Buy |
6,674
+2,130
| +47% | +$452K | 0.28% | 110 |
|
|
2022
Q2 | $927K | Sell |
4,544
-190
| -4% | -$38.8K | 0.15% | 203 |
|
|
2022
Q1 | $997K | Sell |
4,734
-7,848
| -62% | -$1.71M | 0.12% | 223 |
|
|
2021
Q4 | $3.02M | Sell |
12,582
-66
| -0.5% | -$17K | 0.35% | 89 |
|
|
2021
Q3 | $3.58M | Buy |
12,648
+100
| +0.8% | +$32.8K | 0.44% | 65 |
|
|
2021
Q2 | $4.34M | Sell |
12,548
-292
| -2% | -$88.5K | 0.51% | 58 |
|
|
2021
Q1 | $3.59M | Sell |
12,840
-514
| -4% | -$139K | 0.44% | 65 |
|
|
2020
Q4 | $3.27M | Sell |
13,354
-1,330
| -9% | -$343K | 0.41% | 74 |
|
|
2020
Q3 | $4.17M | Buy |
14,684
+3,387
| +30% | +$945K | 0.6% | 32 |
|
|
2020
Q2 | $3.02M | Sell |
11,297
-12,327
| -52% | -$3.71M | 0.5% | 56 |
|
|
2020
Q1 | $7.47M | Sell |
23,624
-5,455
| -19% | -$1.66M | 1.51% | 7 |
|
|
2019
Q4 | $8.63M | Buy |
29,079
+19,879
| +216% | +$5.52M | 1.06% | 13 |
|
|
2019
Q3 | $2.14M | Buy |
+9,200
| New | +$2.14M | 0.31% | 97 |
|
|
2019
Q2 | – | Sell |
-153
| Closed | -$36K | – | 481 |
|
|
2019
Q1 | $36K | Sell |
153
-22,915
| -99% | -$7.22M | 0.01% | 408 |
|
|
2018
Q4 | $6.94M | Sell |
23,068
-27,632
| -55% | -$8.82M | 1.09% | 16 |
|
|
2018
Q3 | $17.9M | Buy |
50,700
+20,300
| +67% | +$6.99M | 2.11% | 3 |
|
|
2018
Q2 | $8.82M | Sell |
30,400
-1,792
| -6% | -$504K | 1.1% | 12 |
|
|
2018
Q1 | $8.81M | Sell |
32,192
-2,628
| -8% | -$816K | 1.16% | 15 |
|
|
2017
Q4 | $11.1M | Sell |
34,820
-2,811
| -7% | -$902K | 1.46% | 10 |
|
|
2017
Q3 | $11.8M | Buy |
37,631
+9,189
| +32% | +$2.72M | 1.6% | 11 |
|
|
2017
Q2 | $7.72M | Buy |
28,442
+3,679
| +15% | +$973K | 1.1% | 13 |
|
|
2017
Q1 | $6.77M | Sell |
24,763
-5,179
| -17% | -$1.46M | 1.06% | 14 |
|
|
2016
Q4 | $8.49M | Buy |
29,942
+19,842
| +196% | +$5.88M | 1.4% | 10 |
|
|
2016
Q3 | $3.16M | Buy |
+10,100
| New | +$2.99M | 0.51% | 45 |
|
|
2016
Q2 | – | Sell |
-10,880
| Closed | -$2.83M | – | 323 |
|
|
2016
Q1 | $2.83M | Buy |
10,880
+167
| +2% | +$44.1K | 0.49% | 44 |
|
|
2015
Q4 | $3.28M | Buy |
10,713
+7,244
| +209% | +$2.08M | 0.51% | 47 |
|
|
2015
Q3 | $1.01M | Buy |
3,469
+234
| +7% | +$77.3K | 0.17% | 139 |
|
|
2015
Q2 | $1.31M | Sell |
3,235
-7,298
| -69% | -$2.93M | 0.2% | 123 |
|
|
2015
Q1 | $4.45M | Sell |
10,533
-4,741
| -31% | -$1.87M | 0.62% | 48 |
|
|
2014
Q4 | $5.18M | Buy |
15,274
+726
| +5% | +$235K | 0.76% | 39 |
|
|
2014
Q3 | $4.81M | Hold |
14,548
| – | – | 0.74% | 39 |
|
|
2014
Q2 | $4.59M | Sell |
14,548
-635
| -4% | -$191K | 0.68% | 37 |
|
|
2014
Q1 | $4.64M | Buy |
15,183
+1,282
| +9% | +$407K | 0.68% | 34 |
|
|
2013
Q4 | $3.89M | Buy |
13,901
+12,141
| +690% | +$3.14M | 0.55% | 45 |
|
|
2013
Q3 | $424K | Buy |
1,760
+141
| +9% | +$31.6K | 0.06% | 275 |
|
|
2013
Q2 | $348K | Buy |
+1,619
| New | +$346K | 0.06% | 256 |
|
Other funds holding BIIB
Essex Investment Management's BIIB Position: Q4 2023 in Review
Essex Investment Management sold out of Biogen (BIIB) in Q4 2023, closing a stake of 4,235 shares — an estimated $1.09M sold.
Essex Investment Management first reported a position in BIIB in Q2 2013 and held it in 40 quarters. The position peaked at $17.9M in Q3 2018. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.
- Essex Investment Management reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
- Essex Investment Management sold 4,235 Biogen shares in Q4 2023, an estimated $1.09M.
- Essex Investment Management first reported a position in Biogen in Q2 2013 and held it in 40 quarters.
- Essex Investment Management's Biogen position peaked at $17.9M in Q3 2018.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.
Based on Essex Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.